Age-related muscle atrophy inhibitor

The anti-aging agent with Juzentaihoto and other herbal extracts addresses age-related muscle atrophy by promoting Sirt1 expression, reducing inflammation, and increasing muscle mass, effectively combating age-related muscle weakness and other aging symptoms.

JP7583434B2Active Publication Date: 2024-11-14NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020181364
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-10-29
Publication Date
2024-11-14
Estimated Expiration
2040-10-29

AI Technical Summary

Technical Problem

There is a need for effective anti-aging agents that can promote the expression of the longevity gene Sirt1 to address age-related muscle atrophy and other aging-related phenotypes such as decreased muscle strength, osteoporosis, increased visceral fat, and cardiovascular decline.

Method used

An anti-aging agent containing Juzentaihoto as an active ingredient, combined with water-soluble components of cinnamon, Astragalus, Cangzhuang, Dangki, Hakushu, Ginseng, and Bukure, promotes the expression of Sirt1, thereby suppressing muscle atrophy and enhancing muscle strength.

Benefits of technology

The agent effectively promotes Sirt1 expression, reducing inflammatory cytokines, increasing muscle mass, and enhancing muscle function, thus providing a significant anti-aging effect by suppressing age-related muscle atrophy and other aging-related symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583434000002
    Figure 0007583434000002
  • Figure 0007583434000003
    Figure 0007583434000003
  • Figure 0007583434000004
    Figure 0007583434000004
Patent Text Reader

Abstract

To provide an anti-aging agent that can promote an expression of a longevity gene Sirt1.SOLUTION: An anti-aging agent contains Juzentaihoto as an active ingredient, and also contains a water-soluble component of cinnamon, a water-soluble component of Astragali Radix, a water-soluble component of Atractylodes lancea and / or Atractylodis rhizoma, a water-soluble component of Ligusticum acutilobum, a water-soluble component of Rehmannia glutinosa, a water-soluble component of ginseng, a water-soluble component of Poria sclerotium, a water-soluble component of Paeoniae Radix, a water-soluble component of Cnidium officinale Makino, and a water-soluble component of Glycyrrhizae Radix as active ingredients.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an anti-aging agent that can promote the expression of the longevity gene Sirt1. [Background technology]

[0002] The average life expectancy in Japan has increased significantly in the latter half of the 20th century, making Japan one of the longest-living countries in the world. However, problems caused by aging have also become more prevalent. For example, phenotypes of aging due to aging include cognitive decline, muscle weakness, osteoporosis, increased visceral fat, decreased cardiovascular function, and insomnia. In particular, muscle weakness due to aging can cause locomotive syndrome, a condition in which mobility is reduced due to disorders of the musculoskeletal system, and may trigger a state in which the person is at high risk of needing nursing care. Therefore, there is a demand for anti-aging agents that can prevent or reduce physical decline due to aging.

[0003] The present inventors have demonstrated through animal experiments that the herbal medicine Juzentaihoto has an inhibitory effect on diabetic muscle atrophy (Non-Patent Documents 1 and 2). However, diabetic muscle atrophy and age-related muscle atrophy are not necessarily related to each other.

[0004] Specifically, muscles and peripheral nerves are connected, and muscle mass and function are maintained by continuous electrical stimulation from the peripheral nerves, but peripheral neuropathy associated with diabetes can impair muscle stimulation and reduce muscle mass. Diabetes can also be accompanied by insulin resistance, and when insulin, which not only lowers blood sugar levels but also promotes cell proliferation and growth, becomes ineffective due to diabetes, muscle cell proliferation and growth can be hindered and muscle mass can decrease. Furthermore, it has been revealed that hyperglycemic conditions caused by diabetes affect certain proteins, resulting in a decrease in muscle mass. In contrast, age-related muscle atrophy refers to muscle atrophy for which no particular cause other than aging has been identified.

[0005] Patent Document 1 also discloses a composition for preventing and / or improving sarcopenia or locomotive syndrome, which contains Goshajinki-gan, a traditional Chinese medicine. Sarcopenia refers to a state in which muscle mass is reduced, resulting in muscle weakness and reduced physical function. Goshajinki-gan is used for numbness, pain in the lower limbs and lower back, swelling, and urinary disorders such as frequent urination at night, which are caused by neuropathy, a diabetic complication. In contrast, Juzen-taiho-to is prescribed for fatigue, anemia, dry skin, loss of appetite, night sweats, cold hands and feet, and other disorders, such as reduced physical strength after illness or surgery, postpartum weakness, anemia, and poor circulation, and its use is fundamentally different from that of Goshajinki-gan, which is used as an active ingredient in Patent Document 1. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 6088044 [Non-patent literature]

[0007] [Non-Patent Document 1] Tomoaki Ishida et al., Biol.Pharm.Bull.,42,1~7(2019) [Non-Patent Document 2] T. Ishida et al., Pharmazie, 75, 9950-1~4(2020) Summary of the Invention [Problem to be solved by the invention]

[0008] As mentioned above, with the advent of an aging society, there is a demand for effective anti-aging agents. Therefore, an object of the present invention is to provide an anti-aging agent that can promote the expression of the longevity gene Sirt1. [Means for solving the problem]

[0009] The present inventors have conducted extensive research to solve the above problems, and as a result have found that Juzentaihoto, which is already used as a traditional Chinese medicine, can promote the expression of the longevity gene Sirt1 and can be effectively used as an active ingredient in anti-aging agents, thus completing the present invention. The present invention will now be described.

[0010] [1] An anti-aging agent characterized by containing Juzentaihoto as an active ingredient. [2] The anti-aging agent described in [1] above, which contains as active ingredients water-soluble components of cinnamon, water-soluble components of astragalus, water-soluble components of Atractylodes Root and / or White Atractylodes Root, water-soluble components of Angelica Root, water-soluble components of Rehmannia Root, water-soluble components of ginseng, water-soluble components of Poria Root, water-soluble components of Peony Root, water-soluble components of Moxibustion Root, and water-soluble components of licorice. [3] The anti-aging agent according to [1] or [2] above, which inhibits muscle atrophy. [4] The anti-aging agent according to any one of [1] to [3], wherein the muscle atrophy is age-related. Effect of the Invention

[0011] The active ingredient of the anti-aging agent of the present invention, Juzentaihoto, is already distributed as a traditional Chinese medicine, and therefore is considered to be relatively safe. In addition, the anti-aging agent of the present invention promotes the expression of Sirt1, which is known as a longevity gene. Sirt1 is known to relax blood vessels and inhibit arteriosclerosis, inhibit amyloid beta deposition and neurodegeneration in the hippocampus to inhibit dementia, and inhibit osteoporosis and skeletal muscle loss. Therefore, the present invention is industrially very excellent as an effective anti-aging agent. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a graph showing the change over time in body weight of normal mice fed normal food, senescence-accelerated mice fed normal food, and senescence-accelerated mice fed food containing the present invention's Juquan Taiho Tang. [Diagram 2] FIG. 2 is a graph showing the results of a rotarod test for normal mice fed a normal diet, senescence-accelerated mice fed a normal diet, and senescence-accelerated mice fed a diet containing the present invention's Juquan Taiho Tang. [Diagram 3] FIG. 3 is a graph showing (A) the serum concentrations of inflammatory cytokines and (B) the serum concentrations of TNFα and IL-6 in normal mice fed normal food, senescence-accelerated mice fed normal food, and senescence-accelerated mice fed food containing the Shiquan Daho Tang of the present invention. [Figure 4] FIG. 4 is a graph showing the serum concentration of the anabolic hormone IGF-1 in normal mice fed a normal diet, senescence-accelerated mice fed a normal diet, and senescence-accelerated mice fed a diet containing the Shiquan Daho Tang of the present invention. [Diagram 5] Figures 5A to 5C are photographs of stained gastrocnemius muscles of normal mice fed normal food, senescence-accelerated mice fed normal food, and senescence-accelerated mice fed food containing the present invention's Juquan Daho Tang, and Figure 5D is a graph showing the cross-sectional area of ​​gastrocnemius muscle fibers of each mouse. [Figure 6] FIG. 6 is a graph showing the expression levels of ubiquitin ligase genes (A) MuRF1 and (B) Atrogin1 in normal mice fed a normal diet, senescence-accelerated mice fed a normal diet, and senescence-accelerated mice fed a diet containing the Shiquan Daho Tang of the present invention. [Figure 7] Figure 7A is a graph showing the expression levels of Sirt1, a longevity gene, in normal mice fed normal food, senescence-accelerated mice fed normal food, and senescence-accelerated mice fed food containing the Shiquan Daho Tang of the present invention, and Figure 7B is a graph showing the correlation between the expression level of Sirt1 and the cross-sectional area of ​​the gastrocnemius muscle in each mouse. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The anti-aging agent of the present invention contains Juzentaihoto as an active ingredient. Juzentaihoto is a traditional Chinese medicine suitable for people who are weak all over and have a severe lack of what is called "ki" and "ketsu" in traditional Chinese medicine. It is prescribed when people have ailments such as fatigue, anemia, dry skin, loss of appetite, night sweats, and cold hands and feet, and is used for various purposes such as improving the overall condition and building up strength, such as improving physical weakness after illness or surgery, postpartum weakness, anemia, and poor circulation.

[0014] Juzen Taihoto contains the water-soluble components of cinnamon bark, water-soluble components of astragalus root, water-soluble components of atractylodes rhizome and / or white atractylodes rhizome, water-soluble components of angelica root, water-soluble components of rehmannia root, water-soluble components of ginseng, water-soluble components of poria root, water-soluble components of peony root, water-soluble components of szechuan radix, and water-soluble components of licorice as active ingredients.

[0015] Cinnamon is the dried bark of the Tonkin Cinnamon tree, which is in the Lauraceae family, and other plants of the same genus. It contains 1-2% essential oils, cinnamon aldehyde, eugenol, safrole, phellandrene, linalool, etc., and is effective as an aromatic stomachic, sudorant, antipyretic, analgesic, intestinal regulating, carminative, and astringent.

[0016] Astragalus root is the dried rhizome of Astragalus membranaceus, which contains flavonoids and saponins and regulates the function of qi, improves gastrointestinal function, restores a weakened body, and relieves swelling and abnormal sweating.

[0017] Soujutsu is the dried rhizome of the Asteraceae plant, which contains hinesol, atractylol, atractyrosin, atractylone, etc., and is effective in strengthening the stomach and intestines, as a diuretic, and inducing sweating. Byakujutsu is the rhizome of the Asteraceae plant or the Oobanaokera plant, which contains sesquiterpenoids and polyacetylene compounds, and is effective in strengthening the stomach, regulating the intestines, and as a diuretic, and is used for water metabolism disorders and digestive system dysfunction. Soujutsu and Byakujutsu may be used either alone or together.

[0018] Angelica is the dried root of the Angelica genus plant in the Umbelliferae family, and contains ligustilide, P-cymene, carvacrol, butylidene phthalide, xanthotoxin, bergapten, isopimpinpinellin, adenine, choline, organic acids (ferulic acid, nicotinic acid, succinic acid, etc.), amino acids, etc., and is effective as a pain reliever, sedative, and tonic.

[0019] Rehmannia is the rhizome of a plant in the genus Rehmannia in the family Scrophulariaceae, and contains catalpol, iridoid glycosides, sugars such as manninotriose, raffinose, stachyose, and mannitol, amino acids such as arginine, and phosphates, and is effective in increasing blood volume, strengthening the body, stopping bleeding, and nourishing the body.

[0020] Ginseng is the dried root of the Korean ginseng plant, which belongs to the Araliaceae family. It contains ginsenosides, which are dammarane triterpenes, as well as numerous saponins, and is effective in treating the stomach and intestines, relieving pain, expectorating, and carminative.

[0021] Poria cocos is the dried sclerotium of the Polyporaceae fungus, with the outer skin removed.It contains tetracyclic triterpene carboxylic acids such as polysaccharides pachyman, pachymaic acid, eburicoic acid, dehydroeburicoic acid, and tumulosic acid, as well as ergosterol, and is effective in diuretic, spleen strengthening, nourishing, sedative, and lowering blood sugar.

[0022] Peony root is the dried root of the Paeonia lactiflora plant, which belongs to the Paeoniaceae family. It contains monoterpene glycosides containing a benzoyl group, such as paeoniflorin, albiflorin, benzoylpaeoniflorin, and tannins, and is effective in relieving pain and spasmolysis, as well as in astringency and relaxation.

[0023] Cnidium officinalis is made by parboiling the rhizomes of Cnidium officinalis (Apiaceae) after removing the fibrous roots, and then drying them.It contains butylphthalide and its related substances, ligustilide, cnidilide, sedanoic acid, etc., and is effective as a blood purifier, sedative, analgesic, blood tonic, etc.

[0024] Licorice is the dried roots and rhizomes of the Glycyrrhiza genus plant of the legume family. It contains triterpenoid saponins such as glycyrrhizin and liquiritin, and isoflavone licoricone, and is effective in treating various acute symptoms, relieving pain, acting as an antispasmodic, detoxifying, and suppressing coughs.

[0025] Juzentaihoto is obtained by hot water extraction of the crushed mixture of each of the above-mentioned herbal medicines. The mixing ratio of each herbal medicine may be adjusted appropriately within the range in which the effect of the present invention can be obtained, but for example, the following ratios may be mixed in total: Cinnamon 9% or more, 12% or less, Astragalus 8% or more, 12% or less, Atractylodes Root and / or Atractylodes Root 9% or more, 13% or less, Angelica Root 9% or more, 13% or less, Rehmannia Root 9% or more, 8% or more, 12% or less, Ginseng 8% or more, Poria Root 9% or more, 13% or less, Peony Root 9% or more, 12% or less, Szechuan Xylocentrotus 9% or more, 12% or less, and Licorice Root 2% or more, 6% or less, totaling 100% by mass, and water of 5 times or more, 25 times or less by mass may be added to the total mixture of crushed herbal medicines, and the mixture is heated and extracted at 80°C or more, 100°C or less for 30 minutes or more, and 2 hours or less, and the solid matter is filtered off. The extract obtained as the filtrate may be used as is or may be dried by freeze-drying or the like.

[0026] The anti-aging agent of the present invention may be the extract itself, or may be a dried product thereof, or may be further formulated.The formulation may be granules, tablets, capsules, etc.The formulation may contain general additives such as excipients such as lactose and crystalline cellulose, binders such as carmellose sodium, disintegrants such as carmellose calcium, lubricants such as magnesium stearate and talc, preservatives, pH adjusters, pigments, and coating agents.

[0027] The dosage of the anti-aging agent of the present invention is not particularly limited and may be adjusted appropriately depending on the patient's age, sex, weight, symptoms, severity, etc., but may be adjusted, for example, in accordance with the dosage of commercially available Juquan Taiho Tang. More specifically, it may be administered to humans or animals at a dose of 5 g or more and 10 g or less per day, calculated as the dried extract, in two or three divided doses.

[0028] The anti-aging agent of the present invention is believed to be capable of suppressing symptoms associated with aging, such as muscle weakness, cognitive decline, osteoporosis, increased visceral fat, decreased cardiovascular function, insomnia, etc. In the present invention, "suppression" includes not only prevention of the onset of symptoms, but also treatment of symptoms once they have occurred, and delaying or alleviating their progression.

[0029] Specifically, the anti-aging agent of the present invention promotes the expression of Sirt1, a longevity gene. Sirt1 contributes to chromosome stabilization by deacetylating histones, and its overexpression has been experimentally confirmed to extend lifespan. Sirt1 is one of the genes of the Sirtuin family, which is a mammalian homolog of Sir2 (Silent Information Regulator-2), whose existence is highly conserved from archaea to mammals. Research on suppressing aging-related diseases such as Alzheimer's dementia, osteoporosis, arteriosclerosis, and skeletal muscle loss by Sirt1 is known, and the present inventors have also experimentally clarified the correlation between the expression level of Sirt1 and the cross-sectional area of ​​skeletal muscle. In addition, the present inventors have experimentally proven that the anti-aging agent of the present invention reduces the serum concentration of inflammatory cytokines that promote muscle breakdown and the expression level of ubiquitin ligase, while increasing the serum concentration of protein anabolic hormones that promote muscle growth, and actually increases the cross-sectional area and weight of muscle fibers of skeletal muscle. Therefore, the anti-aging agent of the present invention is effective in suppressing muscle atrophy, particularly age-related muscle atrophy. EXAMPLES

[0030] The present invention will be described in more detail below with reference to examples. However, the present invention is not limited to the following examples, and it is possible to carry out the present invention by making appropriate modifications within the scope of the above and below-mentioned aims, and all of these modifications are included in the technical scope of the present invention.

[0031] Example 1: Preparation of anti-aging agent 3.0g of Cinnamon, 3.0g of Astragalus, 3.0g of Atractylodes Rhizome, 3.0g of Angelica, 3.0g of Rehmannia Root, 3.0g of Ginseng, 3.0g of Poria Cocos, 3.0g of Peony Root, 3.0g of Szechuan Mushroom, and 1.5g of Licorice were mixed, added to 600g of water, and heated under reflux for 40 minutes. The mixture was allowed to cool to room temperature, and then filtered to remove solids. The filtrate was freeze-dried to obtain 5.0g of an anti-aging agent.

[0032] Test Example 1: Animal Experiments (1) Body weight measurement and rotarod test Thirteen 18-week-old senescence-accelerated mouse SAMP8s and six 18-week-old normal mice SAMR1s were prepared as positive controls, and their weights were measured and the rotarod test was performed. Specifically, each mouse was placed on the roller lane of the rotarod, and the rod was rotated at a constant acceleration of 0.3 rpm / sec. After the rotation speed reached 80 rpm / min, the rod was rotated at a constant speed and the time until the mouse fell off the rod was recorded. Measurements were performed three times for each mouse, and the average was calculated. 18-week-old senescence-accelerated model mice SAMP8 were randomly divided into a negative control group of 6 mice and a group administered with the agent of the present invention of 7 mice. The group administered with the agent of the present invention was allowed to freely consume the anti-aging agent produced in Example 1 mixed in a normal feed ("CLEA Rodent Diet CE-2 for mice, rats and hamsters" manufactured by CLEA Japan) at a ratio of 4 w / w% for 18 weeks. The control group was allowed to freely consume normal feed in which potato starch was mixed in the same normal feed at a ratio of 4 w / w%. Body weight measurements and rotarod tests were performed every 2 weeks from the start of the test until 18 weeks (at 36 weeks of age). The results of the body weight measurements are shown in FIG. 1, and the results of the rotarod test are shown in FIG. 2. In FIG. 1 and FIG. 2, "**" indicates that there was a significant difference of p<0.01 from the results of the negative control group in one-way ANOVA and Bonferroni post-hoc test. As shown in the results in FIG. 1, during the test period, the body weight of the senescence-accelerated mouse model SAMP8 was significantly lower than that of the normal mouse SAMR1, and no significant change in body weight was observed even when the anti-aging agent of the present invention was administered. As shown in the results in Figure 2, the aging-accelerated model mouse SAMP8 had a significantly shorter exercise duration than the normal mouse SAMR1, and muscle weakening was observed. However, when the anti-aging agent of the present invention was administered, a significant improvement in exercise duration was observed 34 to 36 weeks after the start of administration, suggesting a significant increase in muscle mass.

[0033] (2) Blood tests Eighteen weeks after the start of the study (at 36 weeks of age), blood was collected from the descending vena cava and serum concentrations of the inflammatory cytokines TNF-α and IL-6, as well as the anabolic hormone IGF-1, were measured by ELISA. The results for inflammatory cytokines are shown in Figure 3, and the results for IGF-1 in Figure 4. In Figures 3 and 4, "*" indicates that there was a significant difference at p<0.05 compared to the results of the negative control group in one-way ANOVA and Bonferroni post-hoc test, and "**" indicates that there was a significant difference at p<0.01. It has been found that inflammatory cytokines such as TNFα and IL-6 activate NFκB through receptors present in skeletal muscle, and promote muscle degradation by increasing the ubiquitin ligase of the ubiquitin-proteosome system, which is the main protein degradation system in skeletal muscle. In this regard, as shown in the results in Figure 3, the senescence-accelerated mouse model SAMP8 had higher serum concentrations of inflammatory cytokines than the normal mouse SAMR1, suggesting that skeletal muscle degradation is progressing. In contrast, when the anti-aging agent of the present invention was administered, these serum concentrations were significantly reduced, indicating that the degradation of skeletal muscle caused by inflammatory cytokines was significantly suppressed. In addition, anabolic hormones have the effect of promoting muscle growth and enhancing muscle strength and vitality. As shown in the results in FIG. 4, the serum concentration of anabolic hormones in the senescence-accelerated mouse model SAMP8 is significantly lower than that in the normal mouse SAMR1, suggesting a decrease in muscle strength. In contrast, when the anti-aging agent according to the present invention was administered, the serum concentration of anabolic hormones was significantly increased, suggesting a significant increase in muscle strength.

[0034] (3) Muscle evaluation Eighteen weeks after the start of the study (at 36 weeks of age), the gastrocnemius, extensor digitorum longus, and soleus muscles were removed from the lower limbs and the wet weights of each were measured. The results are shown in Table 1. In Table 1, "*" indicates that there was a significant difference at p<0.05 compared to the results of the negative control group in one-way ANOVA and Bonferroni post-hoc test, and "**" indicates that there was a significant difference at p<0.01.

[0035] [Table 1]

[0036] As shown in the results in Table 1, the muscle mass of the lower limbs of the senescence-accelerated mouse model SAMP8 was significantly reduced compared to the normal mouse SAMR1. In contrast, when the anti-aging agent according to the present invention was administered, there was no significant change in the soleus muscle, but the mass of the gastrocnemius muscle and extensor digitorum longus muscle significantly increased.

[0037] In addition, the gastrocnemius muscles were thinly sliced ​​perpendicular to the muscle fibers and stained with HE, and the cross-sectional area of ​​the muscle fibers was measured using the image analysis software WinROOF. Photographs of the stained gastrocnemius muscles in each group are shown in Figures 5A-C, and the cross-sectional area of ​​the gastrocnemius muscle fibers is shown in Figure 5D. In Figure 5D, "*" indicates that there was a significant difference at p<0.05 compared to the results of the negative control group in one-way ANOVA and Bonferroni post-hoc test, and "**" indicates that there was a significant difference at p<0.01. As shown in the results in Figure 5, the cross-sectional area of ​​muscle fibers was significantly reduced in the senescence-accelerated mouse model SAMP8 compared to the normal mouse SAMR1. In contrast, administration of the anti-aging agent according to the present invention significantly increased the cross-sectional area of ​​muscle fibers.

[0038] Furthermore, the expression of ubiquitin ligase genes (MuRF1 and Atrogin1) and longevity gene (Sirt1) in muscle samples was measured by real-time PCR. The results for ubiquitin ligase genes are shown in Figure 6, and the results for longevity gene Sirt1 are shown in Figure 7. In Figures 6 and 7, "*" indicates that there was a significant difference at p<0.05 compared to the results of the negative control group in one-way ANOVA and Bonferroni post-hoc test, and "**" indicates that there was a significant difference at p<0.01. Ubiquitin ligase ubiquitinates insulin receptor substrate-1 (IRS-1), one of the proteins involved in insulin-like growth factor-1 (IGF-1) signaling, which is said to be the most important factor for muscle growth and repair, and promotes the degradation of IRS-1 by the ubiquitin-proteasome system, a specific protein degradation system. As a result, it is known that muscle protein synthesis is reduced and muscle protein degradation is enhanced at the same time due to the reduced IGF-1 signaling. As shown in the results in FIG. 6, the ubiquitin ligase genes MuRF1 and Atrogin1 were significantly more expressed in the aging-accelerated mouse model SAMP8 than in the normal mouse SAMR1. When the anti-aging agent according to the present invention was administered to the mouse, the expression of these ubiquitin ligase genes was significantly suppressed. In addition, the longevity gene Sirt1 promotes the proliferation of myogenic precursor cells (MPC: muscle precursor cells) via cyclin-dependent kinase inhibitor p21, and forms a complex with muscle differentiation regulator MyoD to increase the expression of peroxisome proliferator-activated receptor gamma conjugate PGC-1α, thereby regulating energy metabolism in skeletal muscles. Sirt1 also exhibits antioxidant and anti-inflammatory effects, and has been reported to suppress aging-related diseases such as skin aging, obesity, and dementia, in addition to skeletal muscles. As shown in the results in FIG. 7A, the amount of Sirt1 mRNA produced in the aging-accelerated mouse SAMP8 was significantly lower than that in the normal mouse SAMR1, but when the anti-aging agent according to the present invention was administered, the amount of Sirt1 mRNA produced increased significantly. In addition, as shown in FIG. 7B, a significant correlation was confirmed between the amount of Sirt1 mRNA produced and the cross-sectional area of ​​the gastrocnemius muscle. The above experimental results demonstrate that the anti-aging agent of the present invention inhibits skeletal muscle atrophy and decline in motor function, and exhibits significant anti-aging effects.

Claims

1. An agent for inhibiting age-related muscle atrophy, comprising Juzentaihoto as an active ingredient.

2. 2. An age-related muscle atrophy inhibitor as claimed in claim 1, containing as active ingredients water-soluble components of cinnamon, water-soluble components of astragalus, water-soluble components of Atractylodes Root and / or White Atractylodes Root, water-soluble components of Angelica Root, water-soluble components of Rehmannia Root, water-soluble components of ginseng, water-soluble components of Poria Root, water-soluble components of Peony Root, water-soluble components of Szechuan Mushroom, and water-soluble components of licorice.

3. An agent for inhibiting age-related muscle atrophy according to claim 1 or 2, wherein the Juzen Taiho Tang is an extract of a mixture of 9% by mass or more but 12% by mass or less, Astragalus Root 8% by mass or more but 12% by mass or less, Atractylodes Rhizome and / or Atractylodes Rhizome Root 9% by mass or more but 13% by mass or less, Angelica Root 9% by mass or more but 13% by mass or less, Rehmannia Root 9% by mass or more but 13% by mass or less, Ginseng Root 8% by mass or more but 12% by mass or less, Poria Root 9% by mass or more but 13% by mass or less, Peony Root 9% by mass or more but 12% by mass or less, Szechuan Gui Root 9% by mass or more but 12% by mass or less, and Licorice Root 2% by mass or more but 6% by mass or less, for a total of 100% by mass.

4. An age-related muscle atrophy inhibitor described in any of claims 1 to 3, which is administered at a dose of 5 g or more and 10 g or less per day.

Citation Information

Patent Citations

  • Preparation method of traditional Chinese medicine preparation

    CN101422529A

  • Treatment to make plastic capillary tube hydrophilic

    JP1985088044A

  • Composition for preventing joint aging

    WO2014162925A1